A Phase 3 interventional study of KSI-301 and Sham injection in Non-proliferative Diabetic Retinopathy, sponsored by Kodiak Sciences Inc. Terminated at 61 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-05.
Sponsored by Kodiak Sciences Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 54 under way, 6 of them phase 3. Diabetic Retinopathy · United States.
Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 55th largest by enrollment of the 196 interventional ones that give a count, is one of 18 that started in 2021, is one of 31 in phase 3, and was the 193rd registered.
783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.
Browse Diabetic Retinopathy studies →36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 22+
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Israel and 1 more country
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 1 more country
Ages 18+
Digital Diagnostics, Inc. · Sites in United States
Ages 22+ · Healthy volunteers
BioAge Labs, Inc. · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
267 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 64 · Phase 3 35 · Phase 4 20
First in 1992; this study’s year is marked. 18 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 253 is above the median of 80 across 484 interventional studies indexed under Diabetic Retinopathy.
Median enrollment 72 across the 196 interventional studies, 161 across the 70 observational. Of the 188 that completed or were terminated, 66 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
114 of 267 have an industry lead sponsor. The 10 most frequent:
Kodiak Sciences Inc is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Kodiak Sciences Inc has 4 studies filed under Diabetic Retinopathy — fewer than ten, so there is no comparison to draw.
19 of the studies in Diabetic Retinopathy with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07235085Phase 3Ocular Therapeutix, Inc.A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy | 2027-03 |
| NCT06191094University of Colorado, DenverPre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy | 2026-12 |
| NCT04008121MediBeaconFeasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium | 2026-12 |
| NCT07891910Retina Consultants of DelmarvaIopidine to Decrease Intraocular Pressure Rise After Injections | 2026-12-01 |
| NCT05463289Johns Hopkins UniversityACCESS 2: AI for pediatriC diabetiC Eye examS Study 2 | 2026-12-30 |
Add all 19 to your calendar (.ics) → With an account.
Among the 267 studies in Diabetic Retinopathy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 3 Study will evaluate the efficacy and safety of KSI-301 in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).
This is a Phase 3, prospective, randomized, double-masked, sham-controlled, two-arm, multicenter study evaluating the efficacy and safety of repeated intravitreal dosing of KSI-301 5 mg in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).
The primary endpoint will be assessed at Week 48; additional secondary endpoints for efficacy will be assessed at Week 48, Week 96 and if applicable, over time.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravitreal injection of KSI-301 (5 mg): three initiating doses, and then every 24 weeks through Week 92
Drug: KSI-301
Sham injection on the same schedule as Treatment Group A
Other: Sham injection
Intravitreal injection
The sham injection is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It is performed to maintain masking of the study.
Percentage of Patients Improving ≥2 Steps on DRSS
Percentage of patients improving ≥2 steps on the Diabetic Retinopathy Severity Scale (DRSS) from baseline at Week 48 using last observation carried forward (LOCF). The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Severity range from level 10 (DR absent) to level 85 (advanced proliferative DR: posterior fundus obscured, or center of macula detached).
Time frame: Day 1 to Week 48
Percentage of Patients Developing Any Sight-Threatening Complication
Percentage of patients developing any of the following Sight-Threatening Complication: Proliferative Diabetic Retinopathy (PDR), Anterior segment neovascularization (ASNV), Vitreous hemorrhage or tractional retinal detachment believed to be due to PDR, or Diabetic Macular Edema (DME) from baseline through Week 48
Time frame: Day 1 to Week 48
Percentage of Patients Improving ≥3 Steps on DRSS
Percentage of patients improving ≥3 steps on the Diabetic Retinopathy Severity Scale (DRSS) from baseline at Week 48 using last observation carried forward (LOCF). The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Severity range from level 10 (DR absent) to level 85 (advanced proliferative DR: posterior fundus obscured, or center of macula detached).
Time frame: Day 1 to Week 48
Percentage of Patients Developing PDR
Percentage of patients developing Proliferative Diabetic Retinopathy (PDR) from baseline through Week 48
Time frame: Day 1 to Week 48
Percentage of Patients Developing PDR or ASNV
Percentage of patients developing Proliferative Diabetic Retinopathy (PDR) or Anterior segment neovascularization (ASNV) from baseline through Week 48
Time frame: Day 1 to Week 48
Percentage of Patients Developing Vitreous Hemorrhage or Tractional Retinal Detachment Believed to be Due to PDR
Percentage of patients developing vitreous hemorrhage or tractional retinal detachment believed to be due to Proliferative Diabetic Retinopathy (PDR) from baseline through Week 48
Time frame: Day 1 to Week 48
Percentage of Patients Developing DME
Percentage of patients developing Diabetic Macular Edema (DME) from baseline through Week 48
Time frame: Day 1 to Week 48
Percentage of Patients With a ≥2-step or ≥3-step Worsening on DRSS
Percentage of patients with a ≥2-step or ≥3-step worsening on the Diabetic Retinopathy Severity Scale (DRSS) from baseline at Week 48 using last observation carried forward (LOCF). The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Severity range from level 10 (DR absent) to level 85 (advanced proliferative DR: posterior fundus obscured, or center of macula detached).
Time frame: Day 1 to Week 48
Percentage of Patients Who Lost ≥5, ≥10, or ≥15 Letters in BCVA
Percentage of patients who lost ≥5, ≥10, or ≥15 letters in Best-corrected Visual Acuity (BCVA) from baseline by visit over time. Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity.
Time frame: Day 1 to Week 48
Time to First Development of PDR, ASNV, or DME
Time to first development of Proliferative Diabetic Retinopathy (PDR), Anterior segment neovascularization (ASNV), or Diabetic Macular Edema (DME) through Week 48
Time frame: Day 1 to Week 48
Time to First Development of PDR or ASNV
Time to first development of Proliferative Diabetic Retinopathy (PDR) or Anterior segment neovascularization (ASNV) through Week 48
Time frame: Day 1 to Week 48
Time to First Development of Vitreous Hemorrhage or Tractional Retinal Detachment Believed to be Due to PDR
Time to first development of vitreous hemorrhage or tractional retinal detachment believed to be due to Proliferative Diabetic Retinopathy (PDR) through Week 48
Time frame: Day 1 to Week 48
Time to First Development of DME
Time to first development of Diabetic Macular Edema (DME) through Week 48
Time frame: Day 1 to Week 48
Mean Change in OCT CST
Mean change in Optical Coherence Tomography (OCT) central subfield retinal thickness (CST) from baseline by visit over time
Time frame: Day 1 to Week 48
Mean Change in BCVA
Mean change in Best-corrected Visual Acuity (BCVA) from baseline by visit over time. Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity.
Time frame: Day 1 to Week 48
Participants were recruited based on physician referral at 52 medical centers between September 2021 and August 2022. The first participant was enrolled on 07 September 2021 and the last on 25 August 2022.
| Milestone | KSI-301 - Treatment Group A | Treatment Group B |
|---|---|---|
| Started | 128 | 125 |
| Completed | 120 | 115 |
| Not completed | 8 | 10 |
| Withdrew: Adverse event | 1 | 4 |
| Withdrew: Non-compliance with study schedule | 0 | 1 |
| Withdrew: Withdrawal by subject | 4 | 2 |
| Withdrew: Lost to follow-up | 2 | 3 |
| Withdrew: Participant relocated | 1 | 0 |
| Milestone | KSI-301 - Treatment Group A | Treatment Group B |
|---|---|---|
| Started | 120 | 115 |
| Completed | 0 | 0 |
| Not completed | 120 | 115 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Non-compliance with study schedule | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Lost to follow-up | 3 | 3 |
| Withdrew: Sponsor request | 115 | 111 |
Percentage of patients improving ≥2 steps on the Diabetic Retinopathy Severity Scale (DRSS) from baseline at Week 48 using last observation carried forward (LOCF). The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Severity range from level 10 (DR absent) to level 85 (advanced proliferative DR: posterior fundus obscured, or center of macula detached).
| Participants | KSI-301 - Treatment Group A | Treatment Group B |
|---|---|---|
| Percentage of Patients Improving ≥2 Steps on DRSS | 52 | 2 |
Percentage of patients developing any of the following Sight-Threatening Complication: Proliferative Diabetic Retinopathy (PDR), Anterior segment neovascularization (ASNV), Vitreous hemorrhage or tractional retinal detachment believed to be due to PDR, or Diabetic Macular Edema (DME) from baseline through Week 48
| Participants | KSI-301 - Treatment Group A | Treatment Group B |
|---|---|---|
| Percentage of Patients Developing Any Sight-Threatening Complication | 3 | 26 |
Percentage of patients improving ≥3 steps on the Diabetic Retinopathy Severity Scale (DRSS) from baseline at Week 48 using last observation carried forward (LOCF). The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Severity range from level 10 (DR absent) to level 85 (advanced proliferative DR: posterior fundus obscured, or center of macula detached).
| Participants | KSI-301 - Treatment Group A | Treatment Group B |
|---|---|---|
| Percentage of Patients Improving ≥3 Steps on DRSS | 7 | 0 |
Percentage of patients developing Proliferative Diabetic Retinopathy (PDR) from baseline through Week 48
| Participants | KSI-301 - Treatment Group A | Treatment Group B |
|---|---|---|
| Percentage of Patients Developing PDR | 2 | 10 |
Percentage of patients developing Proliferative Diabetic Retinopathy (PDR) or Anterior segment neovascularization (ASNV) from baseline through Week 48
| Participants | KSI-301 - Treatment Group A | Treatment Group B |
|---|---|---|
| Percentage of Patients Developing PDR or ASNV | 2 | 10 |
Percentage of patients developing vitreous hemorrhage or tractional retinal detachment believed to be due to Proliferative Diabetic Retinopathy (PDR) from baseline through Week 48
| Participants | KSI-301 - Treatment Group A | Treatment Group B |
|---|---|---|
| Percentage of Patients Developing Vitreous Hemorrhage or Tractional Retinal Detachment Believed to be Due to PDR | 2 | 3 |
Percentage of patients developing Diabetic Macular Edema (DME) from baseline through Week 48
| Participants | KSI-301 - Treatment Group A | Treatment Group B |
|---|---|---|
| Percentage of Patients Developing DME | 1 | 17 |
Percentage of patients with a ≥2-step or ≥3-step worsening on the Diabetic Retinopathy Severity Scale (DRSS) from baseline at Week 48 using last observation carried forward (LOCF). The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Severity range from level 10 (DR absent) to level 85 (advanced proliferative DR: posterior fundus obscured, or center of macula detached).
| Participants | KSI-301 - Treatment Group A | Treatment Group B |
|---|---|---|
| Patients with a ≥2-step worsening on DRSS | 1 | 5 |
| Patients with a ≥3-step worsening on DRSS | 0 | 3 |
Percentage of patients who lost ≥5, ≥10, or ≥15 letters in Best-corrected Visual Acuity (BCVA) from baseline by visit over time. Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity.
| Participants | KSI-301 - Treatment Group A | Treatment Group B |
|---|---|---|
| Participants who lost ≥ 5 letters from baseline to Week 8 | 8 | 15 |
| Participants who lost ≥ 5 letters from baseline to Week 20 | 15 | 15 |
| Participants who lost ≥ 5 letters from baseline to Week 32 | 17 | 10 |
| Participants who lost ≥ 5 letters from baseline to Week 44 | 12 | 8 |
| Participants who lost ≥ 5 letters from baseline to Week 48 | 14 | 11 |
| Participants who lost ≥ 10 letters from baseline to Week 8 | 2 | 3 |
| Participants who lost ≥ 10 letters from baseline to Week 20 | 2 | 4 |
| Participants who lost ≥ 10 letters from baseline to Week 32 | 5 | 1 |
| Participants who lost ≥ 10 letters from baseline to Week 44 | 4 | 2 |
| Participants who lost ≥ 10 letters from baseline to Week 48 | 5 | 1 |
| Participants who lost ≥ 15 letters from baseline to Week 8 | 1 | 1 |
| Participants who lost ≥ 15 letters from baseline to Week 20 | 1 | 1 |
| Participants who lost ≥ 15 letters from baseline to Week 32 | 4 | 0 |
| Participants who lost ≥ 15 letters from baseline to Week 44 | 0 | 0 |
| Participants who lost ≥ 15 letters from baseline to Week 48 | 3 | 0 |
Time to first development of Proliferative Diabetic Retinopathy (PDR), Anterior segment neovascularization (ASNV), or Diabetic Macular Edema (DME) through Week 48
| Months | KSI-301 - Treatment Group A | Treatment Group B |
|---|---|---|
| Time to First Development of PDR, ASNV, or DME | NA (NA to NA) | NA (11.5 to NA) |
Time to first development of Proliferative Diabetic Retinopathy (PDR) or Anterior segment neovascularization (ASNV) through Week 48
| Months | KSI-301 - Treatment Group A | Treatment Group B |
|---|---|---|
| Time to First Development of PDR or ASNV | NA (NA to NA) | NA (11.5 to NA) |
Time to first development of vitreous hemorrhage or tractional retinal detachment believed to be due to Proliferative Diabetic Retinopathy (PDR) through Week 48
| Months | KSI-301 - Treatment Group A | Treatment Group B |
|---|---|---|
| Time to First Development of Vitreous Hemorrhage or Tractional Retinal Detachment Believed to be Due to PDR | NA (NA to NA) | NA (NA to NA) |
Time to first development of Diabetic Macular Edema (DME) through Week 48
| Months | KSI-301 - Treatment Group A | Treatment Group B |
|---|---|---|
| Time to First Development of DME | NA (NA to NA) | NA (NA to NA) |
Mean change in Optical Coherence Tomography (OCT) central subfield retinal thickness (CST) from baseline by visit over time
| Microns | KSI-301 - Treatment Group A | Treatment Group B |
|---|---|---|
| Week 8 | -9.8 ± 10.64 | 4.5 ± 17.22 |
| Week 20 | -12.8 ± 13.42 | 6.6 ± 28.99 |
| Week 32 | -13.9 ± 14.88 | 5.2 ± 27.86 |
| Week 44 | -8.9 ± 19.71 | -0.5 ± 17.12 |
| Week 48 | -15.2 ± 16.35 | -0.7 ± 15.76 |
Mean change in Best-corrected Visual Acuity (BCVA) from baseline by visit over time. Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity.
| ETDRS Letters | KSI-301 - Treatment Group A | Treatment Group B |
|---|---|---|
| Week 8 | 1.3 ± 5.02 | 0.2 ± 4.80 |
| Week 20 | 1.1 ± 5.22 | 0.3 ± 6.29 |
| Week 32 | 0.9 ± 8.68 | 1.2 ± 4.87 |
| Week 44 | 1.0 ± 5.63 | 1.6 ± 5.55 |
| Week 48 | 1.1 ± 6.44 | 1.5 ± 5.49 |
Collected over Adverse Events (AEs) reported through the End of Study or Early Termination (ET). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| KSI-301 - Treatment Group A (Day 1 to Week 48) | 1/128 (0.8%) | 18/128 (14.1%) | 49/128 (38.3%) |
| Treatment Group B (Day 1 to Week 48) | 1/125 (0.8%) | 12/125 (9.6%) | 51/125 (40.8%) |
| KSI-301 - Treatment Group A (Post Week 48 to End of Study) | 1/120 (0.8%) | 8/120 (6.7%) | 15/120 (12.5%) |
| Treatment Group B (Post Week 48 to End of Study) | 0/115 (0%) | 3/115 (2.6%) | 9/115 (7.8%) |
| Event | KSI-301 - Treatment Group A (Day 1 to Week 48) | Treatment Group B (Day 1 to Week 48) | KSI-301 - Treatment Group A (Post Week 48 to End of Study) | Treatment Group B (Post Week 48 to End of Study) |
|---|---|---|---|---|
| Chest painGeneral disorders | 1/128 | 0/125 | 2/120 | 0/115 |
| OsteomyelitisInfections and infestations | 1/128 | 2/125 | 2/120 | 0/115 |
| Coronary artery diseaseCardiac disorders | 2/128 | 0/125 | 0/120 | 0/115 |
| Localised infectionInfections and infestations | 2/128 | 0/125 | 0/120 | 0/115 |
| Cerebrovascular accidentNervous system disorders | 0/128 | 1/125 | 0/120 | 1/115 |
| Diabetic footSkin and subcutaneous tissue disorders | 0/128 | 1/125 | 1/120 | 1/115 |
| Back painMusculoskeletal and connective tissue disorders | 0/128 | 0/125 | 0/120 | 1/115 |
| Skin ulcerSkin and subcutaneous tissue disorders | 0/128 | 0/125 | 0/120 | 1/115 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 1/128 | 0/125 | 1/120 | 0/115 |
| Osteomyelitis acuteInfections and infestations | 0/128 | 0/125 | 1/120 | 0/115 |
| Event | KSI-301 - Treatment Group A (Day 1 to Week 48) | Treatment Group B (Day 1 to Week 48) | KSI-301 - Treatment Group A (Post Week 48 to End of Study) | Treatment Group B (Post Week 48 to End of Study) |
|---|---|---|---|---|
| Diabetic retinal oedema - Study EyeEye disorders | 2/128 | 18/125 | 3/120 | 3/115 |
| Diabetes mellitusMetabolism and nutrition disorders | 15/128 | 8/125 | 3/120 | 2/115 |
| Cataract - Study EyeEye disorders | 13/128 | 5/125 | 3/120 | 0/115 |
| HypertensionVascular disorders | 12/128 | 10/125 | 2/120 | 1/115 |
| Conjunctival haemorrhage - Study EyeEye disorders | 9/128 | 4/125 | 1/120 | 0/115 |
| COVID-19Infections and infestations | 9/128 | 6/125 | 1/120 | 0/115 |
| Diabetic retinopathy - Study EyeEye disorders | 2/128 | 8/125 | 1/120 | 3/115 |
| Cataract - Fellow EyeEye disorders | 7/128 | 3/125 | 1/120 | 0/115 |
Full analysis set defined as all randomized subjects who received any study treatment (KSI-301 or sham) and have gradable DRSS value at baseline. Subjects will be analyzed according to their randomized treatment.
| Age, Categorical(Participants) | KSI-301 - Treatment Group A | Treatment Group B | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 96 | 95 | 191 |
| >=65 years | 32 | 30 | 62 |
| Age, Continuous(years) | KSI-301 - Treatment Group A | Treatment Group B | Total |
|---|---|---|---|
| Mean | 56.4 ± 11.39 | 57 ± 9.63 | 56.7 ± 10.54 |
| Sex: Female, Male(Participants) | KSI-301 - Treatment Group A | Treatment Group B | Total |
|---|---|---|---|
| Female | 51 | 56 | 107 |
| Male | 77 | 69 | 146 |
| Ethnicity (NIH/OMB)(Participants) | KSI-301 - Treatment Group A | Treatment Group B | Total |
|---|---|---|---|
| Hispanic or Latino | 57 | 52 | 109 |
| Not Hispanic or Latino | 71 | 73 | 144 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | KSI-301 - Treatment Group A | Treatment Group B | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 2 |
| Asian | 3 | 3 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 13 | 23 | 36 |
| White | 108 | 96 | 204 |
| More than one race | 2 | 0 | 2 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Geographic Region(Participants) | KSI-301 - Treatment Group A | Treatment Group B | Total |
|---|---|---|---|
| North America | 123 | 120 | 243 |
| Rest of World | 5 | 5 | 10 |
| Diabetic Retinopathy Severity Scale (DRSS) at Baseline(Participants) | KSI-301 - Treatment Group A | Treatment Group B | Total |
|---|---|---|---|
| DRSS Level ≤47 | 46 | 45 | 91 |
| DRSS Level ≥53 | 82 | 80 | 162 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2021 to primary completion in Aug 2023, 22 months.
Results were first posted in Sep 2024, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tarcocimab tedromer
Kodiak Sciences Inc